Clear cell carcinoma of the endometrium

Bogani, Giorgio; Concin, Nicole; Ngoi, Natalie; Morice, Philippe; Enomoto, Takayuki; Takehara, Kazuhiro; Denys, Hannelore; Lorusso, Domenica; Coleman, Robert L.; Vaughan, Michelle; Takano, Masashi; Provencher, Diane; Sagae, Satoru; Wimberger, Pauline; Póka, Ròbert; Segev, Yakir; Kim, Jaeweon; Reis, Francisco José Candido dos; Mariani, Andrea; Leitao, Mario M.; Makker, V.; Rustum, Nadeem Abu; Vergote, Ignace; Zannoni, Gian Franco; Tan, David S.P.; McCormack, Mary; Bini, Marta; Lopez, Salvatore; Raspagliesi, Francesco; Panici, Pierluigi Benedetti; Donato, Violante Di; Muzii, Ludovico; Colombo, Nicoletta; Scambia, Giovanni; Pignata, Sandro; Monk, Bradley J.

doi:10.1016/j.ygyno.2022.01.012

Cited by 28 publications

(25 citation statements)

References 25 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This molecular approach improves personalized medicine and tailored treatment, as confirmed in several studies summarized below [8][9][10][11][12]. POLE mutated tumors are characterized by good prognosis, on the contrary p53 abnormal tumors are associated with poor outcomes [8][9][10]. These results were confirmed analyzing data of the PORTEC-1 and PORTEC-2 trials [11].…”

mentioning

confidence: 57%

“…Starting from the evidence reported by The Cancer Genome Atlas (TCGA), the subsequent ProMisE classification have been proposed to classifying four EC groups: (i) POLE (ultra-mutated), (ii) microsatellite instable (MSI-H/MMRdhypermutated), (iii) copy number high (CNH)/TP53 abnormal, and (iv) copy number low (CNL)/TP53 wild type [6,7]. This molecular approach improves personalized medicine and tailored treatment, as confirmed in several studies summarized below [8][9][10][11][12]. POLE mutated tumors are characterized by good prognosis, on the contrary p53 abnormal tumors are associated with poor outcomes [8][9][10].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Molecular markers and endometrial cancer

2022

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

mentioning

confidence: 57%

mentioning

confidence: 99%

Molecular markers and endometrial cancer

2022

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

“…However, positive for hepatocyte nuclear factor 1b and Napsin A. Notably, TP53 is the most commonly mutated gene in ECCC (4,(9)(10)(11). The abnormal p53 expression is considered a poor prognostic factor for EC (11).…”

Section: Discussionmentioning

confidence: 99%

Endometrial clear cell carcinoma: A population-based study

Cui

Cong²,

Zhang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundA systematic analysis of prognostic factors concerning endometrial clear cell carcinoma (ECCC) is lacking. The current study aimed to construct nomograms predicting the overall survival (OS) of ECCC patients.MethodsWe performed a retrospective study, and predicted nomograms for 3-, 5-, and 10-year OS were established. The nomograms were verified with the consistency index (C-index), calibration curve, and decision curve analysis (DCA).ResultsA total of 1778 ECCC patients, 991 from FIGO stage I/II and 787 from FIGO stage III/IV, were included in this study. The age at diagnosis, marital status, T stage, tumor size, and surgery-independent prognostic factors in FIGO stage I/II, and the age at diagnosis, T stage, lymph node involvement, distant metastasis, tumor size, surgery, radiotherapy, and chemotherapy in FIGO stage III/IV were independent prognostic factors. The C-indexes of the training and validation group were 0.766 and 0.697 for FIGO stage I/II and 0.721 and 0.708 for FIGO stage III/IV, respectively. The calibration curve revealed good agreement between nomogram-predicted and actual observation values. The DCA established that nomograms had better clinical benefits than the traditional FIGO stage.ConclusionsThe predicted nomograms showed good accuracy, excellent discrimination ability, and clinical benefits, depicting their usage in clinical practice.

show abstract

“…Moreover, patients having sentinel node mapping are at low risk of developing surgery-related and lymphatic-specific morbidity in comparison to those having lymphadenectomy. Based on growing evidence on the safety and efficacy of sentinel node mapping, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP), the Rare Tumor Working Group (RTWG), and the National Comprehensive Cancer Network (NCCN) guidelines supported the adoption of sentinel node mapping in endometrial cancer, even in highrisk disease [2,3,18,19]. However, we have to highlight that no level A evidence supported the adoption of sentinel node mapping, yet.…”

Section: Evidence Supporting the Adoption Of Sentinel Node Mappingmentioning

confidence: 99%